What is Resmed's earnings per share (EPS)?

Resmed (RSMDF) reported diluted earnings per share of $10.43 for fiscal year 2026. This represents a 9.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Resmed (RSMDF) Financials

RSMDF

FY2026 annual

Revenue $5.7B +9.9% YoY

Net Income $1.5B +8.8% YoY

EPS (Diluted) $10.43 +9.7% YoY

Free Cash Flow $1.6B -0.7% YoY

Source SEC Filings (10-K/10-Q) Latest period FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE June

Newest figures come from the 10-K for FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RSMDF SEC filings page.

Resmed (RSMDF) reported $5.7B in revenue for fiscal year 2026, up 9.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RSMDF FY2026 2026-08-30

Profitable scale is RSMDF’s dominant mechanic: expanding margins turn growth into cash while leverage falls and payouts rise.

Across FY2022-FY2026, revenue expanded while operating margin rose from 28.0% to 33.4%, showing that scale translated into better cost absorption rather than just volume. The cash profile strengthened in parallel: FY2026 operating cash flow was $1.8B and free cash flow was $1.6B, making earnings increasingly deployable.

Margin expansion was broad, with gross margin rising across the period and FY2026 operating margin reaching 33.4%. Because SG&A and R&D also increased in dollars, the improvement reflects revenue growing faster than the operating-cost base, not simple cost cutting.

Balance-sheet capacity improved alongside distributions: debt-to-equity fell from 0.23x in FY2022 to 0.06x in FY2026. That deleveraging coexisted with $1.0B of FY2026 buybacks and dividends, while capex was $156M, indicating cash supported both distributions and reinvestment.

Financial Health Signals

Financial health score not available

Resmed does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Strong

7/9

Resmed passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.19x

For every $1 of reported earnings, Resmed generates $1.19 in operating cash flow ($1.8B OCF vs $1.5B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.5B

YoY+8.6%

QoQ+2.3%

5Y CAGR+10.8%

10Y CAGR+10.9%

Resmed generated $1.5B in revenue in Q4 2026. This represents an increase of 8.6% from the same quarter a year earlier. Against the prior quarter it is up 2.3%.

EBITDA

$493.5M

YoY-4.8%

QoQ-11.7%

5Y CAGR+12.1%

10Y CAGR+13.0%

Resmed's EBITDA was $493.5M in Q4 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 4.8% from the same quarter a year earlier. Against the prior quarter it is down 11.7%.

Net Income

$383.4M

YoY+1.0%

QoQ-3.8%

5Y CAGR+14.5%

10Y CAGR+16.5%

Resmed reported $383.4M in net income in Q4 2026. This represents an increase of 1.0% from the same quarter a year earlier. Against the prior quarter it is down 3.8%.

EPS (Diluted)

$2.64

YoY+2.3%

QoQ-3.6%

5Y CAGR+14.7%

10Y CAGR+14.9%

Resmed earned $2.64 per diluted share (EPS) in Q4 2026. This represents an increase of 2.3% from the same quarter a year earlier. Against the prior quarter it is down 3.6%.

Cash & Balance Sheet

Free Cash Flow

$403.5M

YoY-20.6%

QoQ-22.5%

5Y CAGR+15.2%

10Y CAGR+12.1%

Resmed generated $403.5M in free cash flow in Q4 2026, representing cash available after capex. This represents a decrease of 20.6% from the same quarter a year earlier. Against the prior quarter it is down 22.5%.

Cash & Debt

$1.5B

YoY+21.5%

QoQ-11.5%

5Y CAGR+37.8%

10Y CAGR+7.2%

Resmed held $1.5B in cash against $399.4M in long-term debt as of Q4 2026.

Dividends Per Share

$0.60

YoY+13.2%

QoQ0.0%

5Y CAGR+9.0%

10Y CAGR+7.2%

Resmed paid $0.60 per share in dividends in Q4 2026. This represents an increase of 13.2% from the same quarter a year earlier. It is unchanged from the prior quarter.

Shares Outstanding

144M

YoY-1.5%

QoQ-0.6%

5Y CAGR+297.3%

10Y CAGR+0.2%

Resmed had 144M shares outstanding in Q4 2026. This represents a decrease of 1.5% from the same quarter a year earlier. Against the prior quarter it is down 0.6%.

Margins & Returns

Gross Margin

58.8%

YoY-2.0pp

QoQ-3.4pp

5Y CAGR+2.8pp

10Y CAGR+0.7pp

Resmed's gross margin was 58.8% in Q4 2026, indicating the percentage of revenue retained after direct costs. This is down 2.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.4 percentage points.

Operating Margin

30.7%

YoY-3.1pp

QoQ-4.3pp

5Y CAGR+3.1pp

10Y CAGR+7.8pp

Resmed's operating margin was 30.7% in Q4 2026, reflecting core business profitability. This is down 3.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.3 percentage points.

Net Margin

26.2%

YoY-2.0pp

QoQ-1.7pp

5Y CAGR+3.9pp

10Y CAGR+10.2pp

Resmed's net profit margin was 26.2% in Q4 2026, showing the share of revenue converted to profit. This is down 2.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.7 percentage points.

Return on Equity

5.8%

YoY-0.5pp

QoQ-0.3pp

5Y CAGR-0.9pp

10Y CAGR+0.9pp

Resmed's ROE was 5.8% in Q4 2026, measuring profit generated per dollar of shareholder equity. This is down 0.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.3 percentage points.

Capital Allocation

R&D Spending

$105.7M

YoY+22.3%

QoQ+12.2%

5Y CAGR+12.0%

10Y CAGR+11.9%

Resmed invested $105.7M in research and development in Q4 2026. This represents an increase of 22.3% from the same quarter a year earlier. Against the prior quarter it is up 12.2%.

Share Buybacks

$200.0M

YoY+100.0%

QoQ+14.3%

Resmed spent $200.0M on share buybacks in Q4 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 100.0% from the same quarter a year earlier. Against the prior quarter it is up 14.3%.

Capital Expenditures

$51.1M

YoY+67.2%

QoQ+51.9%

5Y CAGR+12.9%

10Y CAGR+13.5%

Resmed invested $51.1M in capex in Q4 2026, funding long-term assets and infrastructure. This represents an increase of 67.2% from the same quarter a year earlier. Against the prior quarter it is up 51.9%.

RSMDF Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RSMDF quarterly income statement

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	$5.7B+9.9%	$5.1B+9.8%	$4.7B+10.9%	$4.2B+18.0%	$3.6B+11.9%	$3.2B+8.1%	$3.0B+13.4%	$2.6B+11.4%	$2.3B+13.2%	$2.1B+12.4%	$1.8B+9.5%	$1.7B+8.0%	$1.6B+2.7%	$1.5B+10.7%	$1.4B
Cost of Revenue	$2.2B+5.3%	$2.1B+3.0%	$2.0B+8.7%	$1.9B+20.2%	$1.6B+14.4%	$1.4B+9.6%	$1.2B+11.4%	$1.1B+10.7%	$1.0B+16.2%	$865.0M+12.0%	$772.2M+15.7%	$667.5M+18.1%	$565.2M-1.5%	$573.8M+4.8%	$547.8M
Gross Profit	$3.5B+13.0%	$3.1B+15.1%	$2.7B+12.7%	$2.4B+16.4%	$2.0B+10.1%	$1.8B+7.1%	$1.7B+15.0%	$1.5B+11.9%	$1.3B+11.1%	$1.2B+12.7%	$1.1B+5.4%	$1.0B+2.2%	$989.8M+5.2%	$940.7M+14.6%	$820.7M
R&D Expenses	$378.3M+14.2%	$331.3M+7.7%	$307.5M+6.9%	$287.6M+13.4%	$253.6M+12.6%	$225.3M+11.6%	$201.9M+11.8%	$180.7M+16.4%	$155.1M+7.4%	$144.5M+21.8%	$118.7M+3.3%	$114.9M-2.8%	$118.2M-1.6%	$120.1M+9.5%	$109.7M
SG&A Expenses	$1.1B+12.7%	$993.0M+8.3%	$917.1M+4.9%	$874.0M+18.5%	$737.5M+10.0%	$670.4M-0.9%	$676.7M+4.9%	$645.0M+7.4%	$600.4M+8.4%	$554.0M+13.5%	$488.1M+2.0%	$478.6M+6.3%	$450.4M+4.6%	$430.8M+7.0%	$402.6M
Operating Income	$1.9B+11.9%	$1.7B+27.7%	$1.3B+16.6%	$1.1B+13.2%	$1.0B+10.7%	$903.7M+11.6%	$809.7M+39.8%	$579.3M+6.9%	$541.8M+27.3%	$425.8M-0.7%	$429.0M+4.8%	$409.2M+1.0%	$405.1M+14.2%	$354.8M+20.5%	$294.4M
EBITDA	$2.1B+10.8%	$1.9B+25.9%	$1.5B+15.4%	$1.3B+11.8%	$1.2B+9.4%	$1.1B+9.9%	$964.5M+32.1%	$730.1M+10.3%	$661.8M+23.0%	$538.0M+4.3%	$515.8M+6.9%	$482.3M+0.8%	$478.5M+10.5%	$433.1M+13.9%	$380.3M
Interest Expense	N/A	N/A	N/A	-$47.4M-112.3%	-$22.3M-193.0%	$24.0M-40.6%	$40.4M+11.7%	$36.2M+27.5%	$28.4M+0.4%	$28.2M+152.0%	$11.2M+93.9%	$5.8M-5.7%	$6.1M-4.0%	$6.4M+33.5%	$4.8M
Income Tax	$396.1M+43.1%	$276.8M+13.5%	$243.8M+19.5%	$204.1M+12.7%	$181.0M-55.8%	$409.2M+267.2%	$111.4M-2.5%	$114.3M-44.5%	$205.7M+169.1%	$76.5M-12.3%	$87.2M+5.0%	$83.0M-3.2%	$85.8M+10.0%	$78.0M+1.2%	$77.1M
Net Income	$1.5B+8.8%	$1.4B+37.2%	$1.0B+13.7%	$897.6M+15.2%	$779.4M+64.3%	$474.5M-23.7%	$621.7M+53.7%	$404.6M+28.2%	$315.6M-7.8%	$342.3M-2.9%	$352.4M-0.1%	$352.9M+2.2%	$345.3M+12.4%	$307.1M+20.5%	$254.8M
EPS (Basic)	$10.47+9.6%	$9.55+37.6%	$6.94+13.4%	$6.12+14.6%	$5.34+63.3%	$3.27-24.1%	$4.31+52.3%	$2.83+28.1%	$2.21-8.7%	$2.42-3.6%	$2.510.0%	$2.51+2.9%	$2.44+13.5%	$2.15+22.9%	$1.75
EPS (Diluted)	$10.43+9.7%	$9.51+37.4%	$6.92+13.6%	$6.09+14.9%	$5.30	$3.24	$4.27+52.5%	$2.80+27.9%	$2.19-8.8%	$2.40-3.6%	$2.49+0.8%	$2.47+3.3%	$2.39+13.8%	$2.10+22.8%	$1.71
Diluted Shares (Avg)	146M-0.9%	147M-0.1%	148M+0.1%	147M+0.3%	147M	146M	146M+0.8%	144M+0.3%	144M+1.1%	142M+0.6%	142M-0.7%	143M-1.2%	144M-1.4%	146M-1.9%	149M

Metric	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Revenue	$1.5B+8.6%	$1.4B+10.8%	$1.4B+11.0%	$1.3B+9.1%	$1.3B+10.2%	$1.3B+7.9%	$1.3B+10.3%	$1.2B+11.1%
Cost of Revenue	$602.4M+14.1%	$540.4M+2.9%	$544.1M+2.5%	$514.8M+1.5%	$527.9M+4.0%	$525.3M+4.2%	$530.8M+2.9%	$507.3M+1.0%
Gross Profit	$861.2M+5.0%	$891.0M+16.3%	$878.7M+17.0%	$820.8M+14.4%	$820.1M+14.6%	$766.4M+10.6%	$751.3M+16.1%	$717.2M+19.5%
R&D Expenses	$105.7M+22.3%	$94.3M+12.3%	$91.0M+11.8%	$87.3M+9.8%	$86.4M+6.9%	$83.9M+8.9%	$81.4M+10.1%	$79.5M+5.0%
SG&A Expenses	$296.3M+10.9%	$285.7M+16.5%	$278.4M+15.2%	$259.2M+8.5%	$267.2M+10.3%	$245.3M+6.7%	$241.6M+8.8%	$239.0M+7.2%
Operating Income	$448.7M-1.3%	$499.8M+17.3%	$491.7M+17.8%	$446.5M+15.3%	$454.5M+19.2%	$426.3M+13.8%	$417.2M+51.7%	$387.3M+34.0%
EBITDA	$493.5M-4.8%	$558.8M+18.9%	$541.5M+16.8%	$494.2M+14.4%	$518.2M+22.0%	$469.9M+12.4%	$463.7M+45.0%	$432.0M+29.4%
Income Tax	$90.7M+15.8%	$103.6M+96.7%	$103.6M+40.5%	$98.3M+36.2%	$78.3M+19.6%	$52.7M-29.7%	$73.7M+45.5%	$72.1M+36.7%
Net Income	$383.4M+1.0%	$398.7M+9.2%	$392.6M+13.9%	$348.5M+11.9%	$379.7M+29.9%	$365.0M+21.5%	$344.6M+65.0%	$311.4M+41.9%
EPS (Basic)	$2.65+2.3%	$2.74+10.0%	$2.69+14.5%	$2.38+12.3%	$2.59+30.8%	$2.49+22.1%	$2.35+65.5%	$2.12+42.3%
EPS (Diluted)	$2.64+2.3%	$2.74+10.5%	$2.68+14.5%	$2.37+12.3%	$2.58+30.3%	$2.48+21.6%	$2.34+64.8%	$2.11+41.6%
Diluted Shares (Avg)	N/A	146M-1.0%	146M-0.8%	147M-0.5%	N/A	147M-0.2%	147M0.0%	148M+0.1%

Not reported in any period shown, so not listed: Interest Expense.

RSMDF Balance Sheet

RSMDF quarterly balance sheet

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$9.0B+9.7%	$8.2B+18.9%	$6.9B+1.8%	$6.8B+32.5%	$5.1B+7.8%	$4.7B+3.1%	$4.6B+11.7%	$4.1B+34.1%	$3.1B-11.7%	$3.5B+6.5%	$3.3B+49.3%	$2.2B-7.6%	$2.4B+6.8%	$2.2B+3.4%	$2.1B
Current Assets	$4.3B+23.4%	$3.5B+48.7%	$2.4B-0.4%	$2.4B+22.6%	$1.9B+22.7%	$1.6B+3.4%	$1.5B+33.0%	$1.1B+7.5%	$1.1B-35.2%	$1.6B+15.8%	$1.4B+0.8%	$1.4B-9.5%	$1.6B+7.4%	$1.4B+6.4%	$1.4B
Cash & Equivalents	$1.5B+21.5%	$1.2B+407.4%	$238.4M+4.6%	$227.9M-16.7%	$273.7M-7.3%	$295.3M-36.2%	$463.2M+214.8%	$147.1M-22.0%	$188.7M-77.0%	$821.9M+12.4%	$731.4M+2.0%	$717.2M-20.8%	$905.7M+3.4%	$876.0M+8.2%	$809.5M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$945.8M+2.0%	$927.7M+12.8%	$822.3M-17.6%	$998.0M+34.2%	$743.9M+62.8%	$457.0M+9.6%	$416.9M+19.2%	$349.6M+30.1%	$268.7M+0.1%	$268.3M+19.5%	$224.5M-9.1%	$246.9M+49.2%	$165.4M+13.4%	$145.8M-16.3%	$174.4M
Accounts Receivable	$1.0B+10.3%	$939.5M+12.2%	$837.3M+18.8%	$704.9M+22.4%	$576.0M-6.2%	$614.3M+29.4%	$474.6M-10.2%	$528.5M+9.3%	$483.7M+7.4%	$450.5M+17.9%	$382.1M+5.4%	$362.6M+0.8%	$359.6M+13.0%	$318.3M	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$2.9B-4.5%	$3.0B+7.2%	$2.8B+2.6%	$2.8B+43.1%	$1.9B+0.4%	$1.9B+2.0%	$1.9B+1.8%	$1.9B+73.7%	$1.1B+0.4%	$1.1B+0.5%	$1.1B+300.8%	$264.3M-8.7%	$289.3M+5.3%	$274.8M+7.3%	$256.2M
Total Liabilities	$2.4B+7.9%	$2.2B+9.9%	$2.0B-23.4%	$2.6B+51.1%	$1.7B-5.8%	$1.8B-11.9%	$2.1B+2.7%	$2.0B+102.5%	$1.0B-33.4%	$1.5B-3.4%	$1.6B+162.7%	$594.5M-1.4%	$602.7M+0.4%	$600.2M+13.2%	$530.2M
Current Liabilities	$1.4B+36.9%	$1.0B+11.9%	$910.7M+20.1%	$758.5M+10.0%	$689.3M-24.4%	$911.8M+51.3%	$602.8M+8.4%	$556.0M+8.8%	$511.2M+42.0%	$360.1M-43.6%	$638.0M+139.4%	$266.5M-1.1%	$269.6M-53.0%	$574.0M+127.0%	$252.9M
Non-Current Liabilities	$985.4M-17.0%	$1.2B+8.2%	$1.1B-41.1%	$1.9B+78.2%	$1.0B+12.4%	$930.7M-37.4%	$1.5B+0.5%	$1.5B+199.7%	$493.7M-57.0%	$1.1B+24.3%	$923.9M+181.7%	$328.0M-1.5%	$333.2M+1173.7%	$26.2M-90.6%	$277.4M
Long-Term Debt	$399.4M-39.3%	$658.4M-5.6%	$697.3M-51.3%	$1.4B+87.0%	$765.3M+19.0%	$643.4M-44.7%	$1.2B-7.5%	$1.3B+366.3%	$270.0M-75.0%	$1.1B+23.5%	$873.3M+190.5%	$300.6M-0.1%	$300.8M	N/A	$250.8M
Total Equity	$6.6B+10.3%	$6.0B+22.7%	$4.9B+17.8%	$4.1B+22.9%	$3.4B+16.5%	$2.9B+15.6%	$2.5B+20.5%	$2.1B+0.6%	$2.1B+5.0%	$2.0B+15.7%	$1.7B+6.8%	$1.6B-9.7%	$1.8B+9.2%	$1.6B+0.2%	$1.6B
Retained Earnings	$7.3B+19.3%	$6.1B+21.8%	$5.0B+17.4%	$4.3B+17.7%	$3.6B+17.3%	$3.1B+8.7%	$2.8B+16.3%	$2.4B+0.2%	$2.4B+5.0%	$2.3B+7.2%	$2.2B+9.3%	$2.0B+11.0%	$1.8B+12.9%	$1.6B+15.4%	$1.4B

Metric	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Total Assets	$9.0B+9.7%	$8.8B+16.1%	$8.5B+19.1%	$8.3B+15.0%	$8.2B+18.9%	$7.6B+11.0%	$7.1B+3.4%	$7.2B+7.1%
Current Assets	$4.3B+23.4%	$4.1B+26.7%	$3.8B+34.6%	$3.6B+37.3%	$3.5B+48.7%	$3.2B+36.5%	$2.8B+19.3%	$2.6B+14.6%
Cash & Equivalents	$1.5B+21.5%	$1.7B+78.0%	$1.4B+171.5%	$1.4B+224.6%	$1.2B+407.4%	$932.7M+292.0%	$521.9M+148.3%	$426.4M+103.9%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$945.8M+2.0%	$911.9M+5.7%	$922.0M+4.5%	$945.8M+3.0%	$927.7M+12.8%	$862.6M+4.0%	$882.1M-5.5%	$918.0M-4.2%
Accounts Receivable	$1.0B+10.3%	$998.8M+10.0%	$985.6M+14.6%	$907.3M+11.8%	$939.5M+12.2%	$907.8M+16.5%	$859.9M+17.8%	$811.2M+17.2%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$2.9B-4.5%	$3.0B+6.8%	$3.0B+8.5%	$3.0B+5.5%	$3.0B+7.2%	$2.8B+0.5%	$2.8B-2.0%	$2.9B+2.6%
Total Liabilities	$2.4B+7.9%	$2.3B+13.4%	$2.2B+15.6%	$2.2B+7.9%	$2.2B+9.9%	$2.0B-7.5%	$1.9B-22.1%	$2.0B-18.6%
Current Liabilities	$1.4B+36.9%	$1.4B+43.7%	$1.2B+46.5%	$1.3B+38.9%	$1.0B+11.9%	$940.5M+21.7%	$852.0M+11.5%	$904.1M+17.3%
Non-Current Liabilities	$985.4M-17.0%	$941.2M-12.9%	$934.4M-9.8%	$931.6M-17.1%	$1.2B+8.2%	$1.1B-23.5%	$1.0B-37.5%	$1.1B-34.7%
Long-Term Debt	$399.4M-39.3%	$404.2M-39.1%	$403.9M-39.1%	$408.7M-38.8%	$658.4M-5.6%	$663.1M-33.5%	$662.9M-45.5%	$667.6M-50.6%
Total Equity	$6.6B+10.3%	$6.5B+17.1%	$6.3B+20.3%	$6.1B+17.8%	$6.0B+22.7%	$5.5B+19.8%	$5.3B+17.2%	$5.2B+22.2%
Retained Earnings	$7.3B+19.3%	$7.0B+20.4%	$6.6B+21.0%	$6.3B+21.4%	$6.1B+21.8%	$5.8B+21.2%	$5.5B+21.0%	$5.2B+18.7%

RSMDF Cash Flow Statement

RSMDF quarterly cash flow statement

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	$1.8B+3.1%	$1.8B+25.0%	$1.4B+102.1%	$693.3M+97.4%	$351.1M-52.3%	$736.7M-8.2%	$802.3M+74.8%	$459.1M-9.1%	$505.0M+22.0%	$414.1M-24.4%	$547.9M+43.0%	$383.2M-2.1%	$391.3M-2.9%	$402.8M+5.1%	$383.2M
Depreciation & Amortization	$201.3M+1.4%	$198.5M+12.2%	$176.9M+7.1%	$165.2M+3.5%	$159.6M+1.8%	$156.8M+1.2%	$154.8M+2.7%	$150.8M+25.7%	$120.0M+7.0%	$112.2M+29.1%	$86.8M+18.9%	$73.1M-0.5%	$73.5M-6.2%	$78.3M-8.8%	$85.9M
Stock-Based Compensation	$104.3M+13.8%	$91.7M+14.3%	$80.2M+12.7%	$71.1M+9.0%	$65.3M+2.1%	$63.9M+11.1%	$57.6M+10.5%	$52.1M+7.6%	$48.4M+5.4%	$45.9M-1.0%	$46.4M-3.0%	$47.9M+10.1%	$43.5M+13.9%	$38.2M+24.8%	$30.6M
Capital Expenditures	$156.3M+73.9%	$89.9M-9.6%	$99.5M-16.9%	$119.7M-11.2%	$134.8M+31.3%	$102.7M+7.7%	$95.3M+38.7%	$68.7M+9.8%	$62.6M+0.6%	$62.2M+6.3%	$58.5M-6.3%	$62.5M-14.1%	$72.7M+14.4%	$63.6M+34.9%	$47.1M
Free Cash Flow	$1.6B-0.7%	$1.7B+27.6%	$1.3B+126.9%	$573.6M+165.2%	$216.3M-65.9%	$634.0M-10.3%	$706.9M+81.1%	$390.3M-11.8%	$442.4M+25.8%	$351.8M-28.1%	$489.4M+52.6%	$320.7M+0.7%	$318.5M-6.1%	$339.2M+1.0%	$336.0M
Investing Cash Flow	-$545.2M-172.5%	-$200.0M+25.8%	-$269.8M+76.7%	-$1.2B-404.5%	-$229.9M-45.1%	-$158.5M+11.9%	-$179.9M+83.3%	-$1.1B-956.4%	-$101.8M-24.3%	-$81.9M+92.7%	-$1.1B	N/A	N/A	-$78.0M+23.2%	-$101.6M
Financing Cash Flow	-$1.0B-66.1%	-$606.3M+45.8%	-$1.1B-364.7%	$422.9M+429.4%	-$128.4M+83.2%	-$764.6M-141.0%	-$317.3M-154.6%	$580.6M+156.6%	-$1.0B-290.6%	-$262.9M-142.9%	$612.6M	N/A	N/A	-$153.9M+13.1%	-$177.1M
Dividends Paid	$349.7M+12.5%	$310.9M+10.1%	$282.3M+9.3%	$258.3M+5.3%	$245.3M+8.2%	$226.7M+0.7%	$225.1M+6.3%	$211.7M+6.1%	$199.5M+7.1%	$186.3M+10.8%	$168.1M+6.9%	$157.3M+11.1%	$141.5M+45.6%	$97.2M	N/A
Share Buybacks	$700.0M+133.3%	$300.0M+100.0%	$150.0M	$0	$0	N/A	N/A	$22.8M-57.5%	$53.8M	N/A	$102.1M-36.3%	$160.3M-20.7%	$202.2M+8.5%	$186.3M-52.6%	$392.7M

Metric	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Operating Cash Flow	$454.6M-15.6%	$554.1M-4.2%	$339.7M+10.1%	$457.3M+40.5%	$538.8M+22.4%	$578.7M+43.9%	$308.6M+13.1%	$325.5M+13.7%
Depreciation & Amortization	$44.8M-29.6%	$59.0M+35.0%	$49.9M+7.4%	$47.7M+6.6%	$63.6M+45.7%	$43.7M+0.5%	$46.4M+3.7%	$44.7M-0.5%
Stock-Based Compensation	N/A	N/A	N/A	$21.2M+5.0%	N/A	N/A	N/A	$20.2M+8.9%
Capital Expenditures	$51.1M+67.2%	$33.7M+61.8%	$28.5M+38.2%	$43.0M+140.8%	$30.6M+22.9%	$20.8M-1.9%	$20.6M-11.6%	$17.8M-40.6%
Free Cash Flow	$403.5M-20.6%	$520.5M-6.7%	$311.2M+8.1%	$414.4M+34.7%	$508.2M+22.4%	$557.9M+46.5%	$288.0M+15.4%	$307.7M+20.1%
Investing Cash Flow	-$383.7M-186.9%	-$58.0M-82.6%	-$50.9M-38.8%	-$52.6M-2550.0%	-$133.7M-187.5%	-$31.8M+4.1%	-$36.7M+10.8%	$2.1M+101.4%
Financing Cash Flow	-$263.2M-60.6%	-$255.2M-77.2%	-$258.3M-75.1%	-$230.3M-52.7%	-$163.9M+58.3%	-$144.1M+57.1%	-$147.5M+38.3%	-$150.8M+0.2%
Dividends Paid	$87.1M+12.2%	$87.2M+12.3%	$87.6M+12.7%	$87.8M+12.7%	$77.6M+10.0%	$77.7M+10.2%	$77.7M+9.9%	$77.9M+10.3%
Share Buybacks	$200.0M+100.0%	$175.0M+133.3%	$175.0M+133.4%	$150.0M+200.0%	$100.0M+100.0%	$75.0M+50.1%	$75.0M+50.0%	$50.0M

RSMDF Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RSMDF quarterly financial ratios

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	61.1%+1.7pp	59.4%+2.7pp	56.7%+0.9pp	55.8%-0.8pp	56.6%-1.0pp	57.5%-0.6pp	58.1%+0.8pp	57.3%+0.3pp	57.0%-1.1pp	58.1%+0.2pp	58.0%-2.2pp	60.2%-3.4pp	63.6%+1.5pp	62.1%+2.1pp	60.0%
Operating Margin	33.4%+0.6pp	32.8%+4.6pp	28.2%+1.4pp	26.8%-1.2pp	28.0%-0.3pp	28.3%+0.9pp	27.4%+5.2pp	22.2%-0.9pp	23.2%+2.6pp	20.6%-2.7pp	23.3%-1.0pp	24.4%-1.7pp	26.1%+2.6pp	23.4%+1.9pp	21.5%
Net Margin	26.9%-0.3pp	27.2%+5.4pp	21.8%+0.5pp	21.3%-0.5pp	21.8%+6.9pp	14.8%-6.2pp	21.0%+5.5pp	15.5%+2.0pp	13.5%-3.1pp	16.6%-2.6pp	19.2%-1.8pp	21.0%-1.2pp	22.2%+1.9pp	20.3%+1.7pp	18.6%
Return on Equity	23.1%-0.3pp	23.5%+2.5pp	21.0%-0.7pp	21.7%-1.5pp	23.2%+6.8pp	16.4%-8.5pp	24.9%+5.4pp	19.5%+4.2pp	15.3%-2.1pp	17.5%-3.3pp	20.8%-1.4pp	22.2%+2.6pp	19.6%+0.6pp	19.1%+3.2pp	15.8%
Return on Assets	17.0%-0.2pp	17.1%+2.3pp	14.9%+1.6pp	13.3%-2.0pp	15.3%+5.3pp	10.0%-3.5pp	13.6%+3.7pp	9.8%-0.4pp	10.3%+0.4pp	9.9%-1.0pp	10.8%-5.4pp	16.2%+1.6pp	14.6%+0.7pp	13.9%+2.0pp	11.9%
Current Ratio	3.10-0.3x	3.44+0.9x	2.59-0.5x	3.12+0.3x	2.80+1.1x	1.73-0.8x	2.53+0.5x	2.060.0x	2.08-2.5x	4.57+2.3x	2.23-3.1x	5.28-0.5x	5.77+3.2x	2.52-2.9x	5.38
Debt-to-Equity	0.060.0x	0.110.0x	0.14-0.2x	0.35+0.1x	0.230.0x	0.22-0.2x	0.47-0.1x	0.61+0.5x	0.13-0.4x	0.550.0x	0.52+0.3x	0.190.0x	0.17-0.2x	0.37+0.2x	0.16
Asset Turnover	0.630.0x	0.63-0.1x	0.68+0.1x	0.63-0.1x	0.700.0x	0.680.0x	0.640.0x	0.63-0.1x	0.76+0.2x	0.600.0x	0.56-0.2x	0.77+0.1x	0.660.0x	0.690.0x	0.64
FCF Margin	29.2%-3.1pp	32.3%+4.5pp	27.8%+14.2pp	13.6%+7.5pp	6.0%-13.8pp	19.8%-4.1pp	23.9%+8.9pp	15.0%-3.9pp	18.9%+1.9pp	17.0%-9.6pp	26.6%+7.5pp	19.1%-1.4pp	20.5%-1.9pp	22.4%-2.1pp	24.6%

Metric	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Gross Margin	58.8%-2.0pp	62.3%+2.9pp	61.8%+3.2pp	61.5%+2.9pp	60.8%+2.3pp	59.3%+1.5pp	58.6%+3.0pp	58.6%+4.1pp
Operating Margin	30.7%-3.1pp	34.9%+1.9pp	34.6%+2.0pp	33.4%+1.8pp	33.7%+2.6pp	33.0%+1.7pp	32.5%+8.9pp	31.6%+5.4pp
Net Margin	26.2%-2.0pp	27.9%-0.4pp	27.6%+0.7pp	26.1%+0.7pp	28.2%+4.3pp	28.3%+3.2pp	26.9%+8.9pp	25.4%+5.5pp
Return on Equity	5.8%-0.5pp	6.1%-0.4pp	6.2%-0.4pp	5.7%-0.3pp	6.4%+0.4pp	6.6%+0.1pp	6.6%+1.9pp	6.0%+0.8pp
Return on Assets	4.3%-0.4pp	4.5%-0.3pp	4.6%-0.2pp	4.2%-0.1pp	4.7%+0.4pp	4.8%+0.4pp	4.8%+1.8pp	4.3%+1.1pp
Current Ratio	3.10-0.3x	3.01-0.4x	3.06-0.3x	2.890.0x	3.44+0.9x	3.41+0.4x	3.33+0.2x	2.92-0.1x
Debt-to-Equity	0.060.0x	0.06-0.1x	0.06-0.1x	0.07-0.1x	0.110.0x	0.12-0.1x	0.13-0.1x	0.13-0.2x
Asset Turnover	0.160.0x	0.160.0x	0.170.0x	0.160.0x	0.160.0x	0.170.0x	0.180.0x	0.170.0x
FCF Margin	27.6%-10.1pp	36.4%-6.8pp	21.9%-0.6pp	31.0%+5.9pp	37.7%+3.7pp	43.2%+11.4pp	22.5%+1.0pp	25.1%+1.9pp

Where Resmed Ranks

Frequently Asked Questions

What is Resmed's annual revenue?

Resmed (RSMDF) reported $5.7B in total revenue for fiscal year 2026. This represents a 9.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Resmed's revenue growing?

Resmed (RSMDF) revenue grew by 9.9% year-over-year, from $5.1B to $5.7B in fiscal year 2026.

Is Resmed profitable?

Yes, Resmed (RSMDF) reported a net income of $1.5B in fiscal year 2026, with a net profit margin of 26.9%.

What is Resmed's EBITDA?

Resmed (RSMDF) had EBITDA of $2.1B in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Resmed have?

As of fiscal year 2026, Resmed (RSMDF) had $1.5B in cash and equivalents against $399.4M in long-term debt.

What is Resmed's gross margin?

Resmed (RSMDF) had a gross margin of 61.1% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is Resmed's operating margin?

Resmed (RSMDF) had an operating margin of 33.4% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is Resmed's net profit margin?

Resmed (RSMDF) had a net profit margin of 26.9% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

Does Resmed pay dividends?

Yes, Resmed (RSMDF) paid $2.40 per share in dividends during fiscal year 2026.

What is Resmed's return on equity (ROE)?

Resmed (RSMDF) has a return on equity of 23.1% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Resmed's free cash flow?

Resmed (RSMDF) generated $1.6B in free cash flow during fiscal year 2026. This represents a -0.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Resmed's operating cash flow?

Resmed (RSMDF) generated $1.8B in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are Resmed's total assets?

Resmed (RSMDF) had $9.0B in total assets as of fiscal year 2026, including both current and long-term assets.

What are Resmed's capital expenditures?

Resmed (RSMDF) invested $156.3M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does Resmed spend on research and development?

Resmed (RSMDF) invested $378.3M in research and development during fiscal year 2026.

Does Resmed buy back shares?

Yes, Resmed (RSMDF) spent $700.0M on share buybacks during fiscal year 2026, returning capital to shareholders by reducing shares outstanding.

How many shares does Resmed have outstanding?

Resmed (RSMDF) had 144M shares outstanding as of fiscal year 2026.

What is Resmed's current ratio?

Resmed (RSMDF) had a current ratio of 3.10 as of fiscal year 2026, which is generally considered healthy.

What is Resmed's debt-to-equity ratio?

Resmed (RSMDF) had a debt-to-equity ratio of 0.06 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Resmed's return on assets (ROA)?

Resmed (RSMDF) had a return on assets of 17.0% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Resmed's Piotroski F-Score?

Resmed (RSMDF) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Resmed's earnings high quality?

Resmed (RSMDF) has an earnings quality ratio of 1.19x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.